This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): AI 401
Description: AI-401 is an oral or nasally delivered formulation of recombinant human insulin for the prevention of diabetes.
Deal Structure: In December 1994, AutoImmune entered into a license and collaborative agreement with Eli Lilly and Company under which Eli Lilly initiated support for clinical testing of AutoImmune's AI 401.
In April 1999, AutoImmune and Eli Lilly restructured their agreement on AI-401. Under the restructured agreement, Eli Lilly received a non-exclusive research license to complete the studies of AI-401 and agreed to provide AutoImmune with full access to the clinical data. AutoImmune has regained control of all rights to the product and the underlying technology.
Partners: Eli Lilly & Company
AI 401 News
Pink Sheet Lilly/Autoimmune
Additional information available to subscribers only: